| 董启超,梁 晖,胡 聪,林 旭,林智文.奥曲肽治疗急性弥漫性腹膜炎术后患者的临床疗效及对血清内毒素和TNF-α、IL-6水平的影响[J].现代生物医学进展英文版,2018,(8):1536-1539. |
| 奥曲肽治疗急性弥漫性腹膜炎术后患者的临床疗效及对血清内毒素和TNF-α、IL-6水平的影响 |
| Clinical Efficacy of Octreotide in the Treatment of Patients with Acute Diffuse Peritonitis and Influence on the Serum Endotoxin and TNF-α and IL-6 Levels |
| Received:July 10, 2017 Revised:July 31, 2017 |
| DOI：10.13241/j.cnki.pmb.2018.08.028 |
| 中文关键词: 急性弥漫性腹膜炎 奥曲肽 临床疗效 内毒素 肿瘤坏死因子-α 白细胞介素-6 |
| 英文关键词: Acute diffuse peritonitis Octreotide Curative effect Endotoxin Tumor necrosis factor-α Interleukin-6 |
| 基金项目:广东省自然科学基金项目（S201201000916） |
|
| Hits: 607 |
| Download times: 335 |
| 中文摘要: |
| 摘要 目的：探讨奥曲肽治疗急性弥漫性腹膜炎术后患者的临床疗效及对血清内毒素和肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平的影响。方法：收集我院2014年5月~2016年5月收治的86例急性弥漫性腹膜炎患者，按照不同治疗方式分作对照组与研究组，每组43例。两组均采用手术治疗，对照组术后予以常规治疗，研究组基于对照组加以奥曲肽治疗，两组均持续治疗14天。比较两组临床疗效，治疗前后血清内毒素和TNF-α，IL-6水平的变化及不良反应发生情况。结果：治疗后，研究组总有效率显著高于对照组(P<0.05)；两组血清内毒素和TNF-α、IL-6水平均较治疗前显著下降，且研究组上述指标明显低于对照组(P<0.05)。研究组不良反应发生率显著低于对照组(P<0.05)。结论：奥曲肽可显著提高急性弥漫性腹膜炎术后患者的临床疗效，有效降低血清内毒素和IL-6、TNF-α水平，且安全性较高。 |
| 英文摘要: |
| ABSTRACT Objective: To research the clinical efficacy of octreotide in the treatment of patients with acute diffuse peritonitis and influence on the serum endotoxin and Tumor necrosis factor-α(TNF-α), interleukin-6(IL-6) levels. Methods: 86 cases o patients with acute diffuse peritonitis admitted from May 2014 to May 2016 were collected and divided into the control group and the research group with 43 cases in each group according to different treatment methods. Both groups were treated with surgical treatment, and the control group was treated with routine treatment after operation, while the research group was treated with octreotide based on the control group, both groups were continuously treated for 14 days. The clinical efficacy, changes of serum endotoxin and TNF-α, IL-6 level before and after treatment and incidence of adverse reactions were compared between two groups. Results: The total effective rate of research group was 93.02%, which was significantly higher than that of the control group(74.42%, P<0.05). After treatment, the serum endotoxin and TNF-α and IL-6 levels of both group were significantly decreased, which were obviously lower in the research group than those of the control group(P<0.05). The incidence of adverse reactions of research group was 6.97%, which was lower than that of the control group (37.21%, P<0.05). Conclusion: Octreotide can enhance the clinical efficacy of acute diffuse peritonitis patients with high safety, and reduce the levels of serum endotoxin and IL-6 and TNF-α. |
|
View Full Text
View/Add Comment Download reader |
| Close |
